Decera Clinical Education Infectious Disease Podcast

In this episode, Timothy J. Wilkin, MD, MPH, provides a case-based overview of switching antiretroviral therapy in a patient with viral suppression on their current regimen who has a history of virologic failure with drug-resistance mutations. Key findings from 2 relevant studies—the SWITCHMRK trial and Study 380-4030—are reviewed. The case discussion also highlights several other challenges that can be encountered in the switch setting, including incomplete immune recovery, comorbidities, and gastrointestinal intolerability of some antiretroviral drugs.Presenter:Timothy J. Wilkin, MD, MPH​Professor Medicine​Division of Infectious Diseases​Weill Medical College of Cornell University​New York, New YorkContent based on an online CME/CE program supported by an independent educational grant from ViiV Healthcare. Link to full program: https://bit.ly/3VIsDTgFollow along with the slides at https://bit.ly/3DdP3F6 Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this episode, Tristan J. Barber, MA, MD, FRCP, and Darcy Wooten, MD, discuss switching ART with virologic suppression, including:Switching with prior or unknown resistanceData on switching to BIC/FTC/TAF with a preexisting M184V/I mutation from a pooled analysis of 6 phase III studiesThe impact of baseline resistance on outcomes following a switch to BIC/FTC/TAF in Black PWH from the BRAAVE 2020 studyA post hoc analysis of the SALSA study of DTG/3TC outcomes at Week 48 by baseline resistanceData from the SOLAR 3D study on switching to DTG/3TC from a 3- or 4-drug ART regimen with a history of M184VA retrospective analysis of switching to DTG/3TC with archived M184V/I from the French Dat’AIDS CohortSwitching to long-acting ARTGuidance on candidates for LA CAB + RPVData on risk factors for virologic failure with LA CAB + RPVConsidering an ART switch after weight gainData on weight gain after ART initiation by ARV class and drugMean change in weight by sex at Week 96 in the ADVANCE studyDHHS guideline recommendations regarding weight gain with ARTTristan J. Barber, MA, MD, FRCPHonorary Associate ProfessorInstitute for Global HealthUniversity College LondonConsultant in HIV MedicineIan Charleson Day CentreRoyal Free HospitalLondon, United Kingdom Darcy Wooten, MDAssociate Professor of MedicineDivision of Infectious Diseases and Global Public HealthDepartment of MedicineUniversity of California, San DiegoSan Diego, California Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this episode, Lilian Abbo, MD, FIDSA; Julie Ann Justo, PharmD, MS; and David van Duin, MD, PhD, FIDSA, FAST, discuss key concepts about extraintestinal pathogenic Escherichia coli, including:Diverse strains and virulence factors associated with invasive diseaseAntimicrobial resistance profiles seen in clinical practiceVarious disease manifestationsPrevalence and burden of invasive infectionsPopulations at riskRisk factors for multidrug-resistant strainsEmerging vaccine technologiesActive clinical trials Benefits of vaccines and the challenges associated with developmentImportance of antimicrobial stewardship and potential role of vaccines to reduce antimicrobial resistanceProgram Director: Lilian Abbo, MD, FIDSAAssociate Chief Medical Officer in Infectious DiseasesJackson Health SystemProfessor of Infectious DiseasesDepartment of Medicine & Miami Transplant InstituteUniversity of Miami Miller School of MedicineMiami, FloridaFaculty:Julie Ann Justo, PharmD, MSClinical Associate ProfessorDepartment of Clinical Pharmacy and Outcomes SciencesUniversity of South Carolina College of PharmacyInfectious Diseases Clinical Pharmacy SpecialistDepartment of PharmacyPrisma Health Richland HospitalColumbia, South CarolinaDavid Van Duin, MD, PhD, FIDSA, FASTProfessor of Medicine Director, Immunocompromised Host Infectious Diseases ProgramDivision of Infectious DiseasesUniversity of North CarolinaChapel Hill, North CarolinaContent based on a CME program supported by an educational grant from Janssen Therapeutics.Follow along with a downloadable slideset at:https://bit.ly/3eG29BnLink to full program:https://bit.ly/3eFHfCl Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this podcast, Gary S. Marshall, MD, summarizes the burden of meningococcal disease and the importance of immunization, including: The unpredictability and severity of meningococcal diseaseDifferences between meningococcal serogroups and available vaccines Current meningococcal vaccine recommendations, distinguishing between routine vs shared clinical decision-making recommendations Vaccine recommendations in high-risk populations Use of immunization platforms to help complete age-appropriate vaccines, including the MenACWY and MenB vaccine, in adolescents and young adultsFaculty:Gary S. Marshall, MDProfessor of PediatricsDivision of Pediatric Infectious DiseasesUniversity of Louisville School of MedicineLouisville, KentuckyLink to full program:https://bit.ly/3T0GLG2 Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this episode, Cristina Mussini, MD, shares her approach to caring for aging patients with HIV. This includes not just focusing on their HIV, but their over well-being, such as:Maintaining a healthy weight, eating healthy and staying mobile Overcoming the obstacle of stigma from society and self-stigmaEmpowering patients to care for themselvesIn women who are often caregivers most of their life:Encouraging self-careStaying up to date with preventive care such as cancer screenings (eg, mammography, annual Pap smear, and colonoscopy)Teaching patients to love themselvesMaking sure the patient knows you truly care for themFaculty:Cristina Mussini, MDHead of Department of Infectious Diseases and Tropical MedicineFull Professor of Infectious DiseasesInfectious Diseases Clinics, University HospitalUniversity of Modena and Reggio EmiliaModena, ItalyLink to full program:https://bit.ly/3KkF4iZ Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

How do we define “older” in our older patients living with hepatitis B virus (HBV)? What monitoring and treatment options should be considered for these older patients with chronic HBV infection?Listen as Nancy Reau, MD, discusses strategies and considerations for monitoring and treating older adults with HBV, illustrated with a patient case.Presenter:Nancy Reau, MDProfessor of MedicineChief, Section of Hepatology Associate Director, Solid Organ Transplantation Richard B. Capps Chair of HepatologyRush University Medical CenterChicago, IllinoisLink to full program:https://bit.ly/3T1UImw Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this episode, listen to Priscilla Y. Hsue, MD, and Jens D. Lundgren MD, DMSc, discuss the latest data about ARV-related weight gain and cardiometabolic toxicities in PWH. Hear faculty:Review risk factors associated with significant weight gainConsider possible implications of weight gain and cardiometabolic toxicitiesShare their approaches to ARV-related weight gain and/or cardiometabolic toxicitiesFaculty:Priscilla Y. Hsue, MDProfessor of MedicineUniversity of California at San FranciscoSan Francisco General HospitalSan Francisco, CaliforniaJens D. Lundgren, MD, DMScProfessorRigshospital, University of CopenhagenDirectorCentre of Excellence for Health, Immunity and Infection (CHIP)Rigshospital, University of CopenhagenCopenhagen, DenmarkLink to full program:https://bit.ly/3PM3nYe Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this episode, Chloe Orkin, MBChB, FRCP, MD, discusses new HIV data from AIDS 2022, including:Prevention strategiesOral therapiesLA therapiesCureCOVID-19 in PWHFacultyChloe Orkin, MBChB, FRCP, MDProfessor of HIVQueen Mary, University of LondonConsultant PhysicianLead for HIV ResearchBarts Health NHS TrustThe Royal London HospitalLondon, United KingdomFollow along with the slides atbit.ly/3SLuhBq Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this episode, Roger Bedimo, MD, MS, FACP, discusses key considerations for switching ART in virologically suppressed patients who are pregnant or trying to conceive. His discussion includes:DHHS Perinatal Guideline recommendationsFrench Perinatal Cohort study on the implications of viral suppression when changing ART in the first trimester of pregnancyIMPAACT 2010 Update on the safety and efficacy of DTG vs EFV and TDF vs TAF in pregnancyDolPHIN-2 study of virological suppression with DTG- vs EFV-based ART started in late pregnancyPresenter:Roger Bedimo, MD, MS, FACPProfessor of MedicineDivision of Infectious DiseasesUniversity of Texas Southwestern Medical CenterSection ChiefDivision of Infectious DiseasesDepartment of Internal MedicineVA North Texas Health Care SystemDallas, TexasContent based on an online CME program supported by an independent educational grant from ViiV Healthcare.Link to full program: https://bit.ly/3UYTF8QFollow along with the slides at https://bit.ly/3CqhrmU Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this podcast, Melanie Reese, a woman aging with HIV, shares her perspectives on the added challenges faced by older women with HIV—an underserved, underresourced, and underresearched group—and talks about potential solutions that should be considered, such as:Listen and prioritize concerns brought to you by older women with HIV to improve trust in you and the medical professionPromote self-advocacy for women to improve their interactions with healthcare professionals, such as opening the dialogue about sexual healthSupport mental health by ensuring a baseline neurologic exam to monitor for any cognitive declineEmphasize the importance of self-care and prioritizing oneselfAddress psychosocial issues by finding ways for patients to connect with othersAdvocate to change policies, standards of care, and laws that govern all places that care for those who are aging and need assistance in careFacultyMelanie ReeseSubject Matter Expert, HIV AgingTechnical Expert PanelHealth Resources and Services AdministrationHIV/AIDS BureauBaltimore, MarylandLink to full program: https://bit.ly/3KkF4iZ Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this episode, listen to Dorothy Onyango, patient and patient activist, share her views on the many barriers encountered by aging patients with HIV living in resource-limited settings and the need to work on solutions to overcome such barriers, including:The major burden of poverty affecting access to care/medications, healthcare services (eg, treatment for noncommunicable diseases, home-based care), and social supportThe added social obstructions to HIV care for older women (eg, sexual reproductive health rights)Potential solutions to support the aging population with HIV to encourage good health and wellness such as:Self-advocacy to provide a voice for patients, especially womenA comprehensive public health responsePolicy changes, including a budget line in the national budget, to ensure the rights of older peopleAIDS-friendly prevention initiatives (eg, affordable/accessible condoms)Income-generating activities to help older patients with HIV become economically soundFaculty:Dorothy OnyangoChief Executive OfficerWomen Fighting AIDS in KenyaFounding Member, International Community of Women Living With HIVFormer Chair, Pan African Women’s CoalitionFormer Board Member, Kenya National AIDS CouncilNairobi, KenyaLink to full program:https://bit.ly/3yIkntc Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this episode, an international expert panel shares their thoughts on key considerations for incorporating long-acting cabotegravir as an additional HIV pre-exposure prophylaxis option for appropriate individuals at high risk of acquiring HIV infection.Topics include anticipated patient interest in this new paradigm, the role of the oral lead-in phase, new guideline recommendations for monitoring during PrEP, patient care and follow-up after PrEP discontinuation, and remaining unanswered questions.Other episodes in this 4-part series cover additional aspects of long-acting antiretrovirals for HIV treatment and prevention, including key steps for switching patients to long-acting injectable cabotegravir plus rilpivirine for HIV treatment, such as selecting the most appropriate patients, introducing patients to the long-acting option, and preparing patients for what to expect from long-acting treatment in terms of efficacy, visit timing, and the injection experience; key considerations at the operational level for incorporating long-acting injectable ART into the HIV treatment armamentarium; and what is still needed in long-acting HIV care to further address patient needs and inequities across subgroups.Presenters:Babafemi Taiwo, MBBSGene Stollerman Professor of MedicineChief, Division of Infectious DiseasesNorthwestern University Feinberg School of MedicineChicago, IllinoisYvonne Gilleece, MB BCh, BAOHonorary Clinical Professor in HIV Medicine and Sexual HealthDepartment of Global Health & HIVBrighton & Sussex Medical SchoolConsultant in HIV Medicine and Sexual HealthHIV DepartmentUniversity Hospitals Sussex NHS Foundation TrustBrighton, United Kingdom Cristina Mussini, MDHead of Department of Infectious Diseases and Tropical MedicineFull Professor of Infectious DiseasesInfectious Diseases Clinics, University HospitalUniversity of Modena and Reggio EmiliaModena, ItalyDarrell H. S. Tan, MD, FRCPC, PhDAssociate ProfessorDivision of Infectious DiseasesUniversity of TorontoClinician-ScientistDivision of Infectious DiseasesSt. Michael's HospitalToronto, CanadaContent based on an online CME/CE program supported by an independent educational grant from ViiV Healthcare. Link to full program:https://bit.ly/3P3uPBc Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this podcast, Jonathan Appelbaum, MD, FACP, AAHIVS, summarizes the many medical challenges faced by aging people with HIV, including:Underrepresentation of older patients in medical researchConsequences of early experiences in the epidemic such as late HIV diagnosis and low CD4+ cell count nadir, incomplete or short-lived virologic suppression with early regimens, and toxicity associated with early antiretroviral agentsAdded challenges of multimorbidity and psychosocial challenges, especially mental health issues, loneliness, and social isolationThe need to provide care for the aging HIV population using a holistic approach Gaps in the current healthcare system in providing optimal care for aging people with HIVFaculty:Jonathan Appelbaum, MD, FACP, AAHIVSLaurie L. Dozier Jr, MD, Education DirectorProfessor of Internal MedicineChair, Department of Clinical SciencesFlorida State University College of MedicineTallahassee, FloridaLink to full program: https://bit.ly/3KkF4iZ Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this episode, Nagalingeswaran Kumarasamy, MBBS, FRCP, PhD, discusses the importance of linking people to care after a positive HIV diagnosis. His overview includes:HIV care continuumFactors that delay linkage to careOrganized strategies to improve linkage to care for people with HIVInterventions that may improve linkage to care for people with HIVPatient perspective on how to engage patients in their HIV care Presenter:Nagalingeswaran Kumarasamy, MBBS, FRCP, PhD​Chief and DirectorVHS Infectious Diseases Medical Centre​Director, Chennai Antiviral Research and Treatment (CART) Clinical Research Site​Voluntary Health Services​Chennai, IndiaPanelists:Linda-Gail Bekker, MBChB, DTM&H, DCH, FCP(SA), PhD​Director​Desmond Tutu HIV Centre​Past President​International AIDS Society​Faculty of Health Sciences​University of Cape TownCape Town, South Africa​Chloe Orkin, MBChB, FRCP, MD​Professor of HIVQueen Mary, University of London​Consultant Physician​Lead for HIV ResearchBarts Health NHS Trust​The Royal London Hospital​London, United Kingdom​Content based on an online CME program supported by an independent educational grant from Gilead Sciences.Follow along with the slides: https://bit.ly/3PJ4iJ8Link to full program:https://bit.ly/3AE2AV1 Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this episode, Babafemi Taiwo, MBBS, discusses strategies for reaching people with HIV who are not yet diagnosed. His overview includes:HIV diagnosis by global regionDisparities in serostatus awarenessPatient perspective on importance of HIV testingBarriers to HIV diagnosisComplications from late HIV diagnosisStrategies to improve rates of HIV testingPresenter:Babafemi Taiwo, MBBS​Gene Stollerman Professor of Medicine​Chief, Division of Infectious Diseases​Northwestern UniversityFeinberg School of Medicine​Chicago, IllinoisPanelists:Linda-Gail Bekker, MBChB, DTM&H, DCH, FCP(SA), PhDDirectorDesmond Tutu HIV Centre​Past PresidentInternational AIDS Society​Faculty of Health SciencesUniversity of Cape TownCape Town, South Africa​Nagalingeswaran Kumarasamy, MBBS, FRCP, PhD​Chief and DirectorVHS Infectious Diseases Medical Centre​Director, Chennai Antiviral Research and Treatment (CART) Clinical Research Site​Voluntary Health Services​Chennai, IndiaChloe Orkin, MBChB, FRCP, MDProfessor of HIVQueen Mary, University of London​Consultant Physician​Lead for HIV ResearchBarts Health NHS Trust​The Royal London Hospital​London, United Kingdom​Content based on an online CME program supported by an independent educational grant from Gilead Sciences.Follow along with the slides: https://bit.ly/3PJRthDLink to full program:https://bit.ly/3AE2AV1 Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this episode, Chloe Orkin, MBChB, FRCP, MD​, discusses strategies for successful antiretroviral therapy (ART) initiation. Her overview includes:Recommendations for rapid ARTFirst-line ART regimens for treatment-naive people with HIVIMEA 055 FAST studySTAT studyDIAMOND studyAntiretroviral resistance mutationsPatient perspectives on the importance of rapid ART initiationPresenter:Chloe Orkin, MBChB, FRCP, MDProfessor of HIVQueen Mary, University of London​Consultant Physician​Lead for HIV ResearchBarts Health NHS Trust​The Royal London Hospital​London, United Kingdom​Panelists:Linda-Gail Bekker, MBChB, DTM&H, DCH, FCP(SA), PhD​DirectorDesmond Tutu HIV Centre​Past PresidentInternational AIDS Society​Faculty of Health SciencesUniversity of Cape TownCape Town, South Africa​Nagalingeswaran Kumarasamy, MBBS, FRCP, PhD​Chief and DirectorVHS Infectious Diseases Medical Centre​Director, Chennai Antiviral Research and Treatment (CART) Clinical Research Site​Voluntary Health Services​Chennai, IndiaBabafemi Taiwo, MBBS​Gene Stollerman Professor of Medicine​Chief, Division of Infectious Diseases​Northwestern UniversityFeinberg School of Medicine​Chicago, IllinoisContent based on an online CME program supported by an independent educational grant from Gilead Sciences.Follow along with the slides: https://bit.ly/3dSNoumLink to full program:https://bit.ly/3AE2AV1 Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this episode, hear Dr. Jean Rene Anderson and Dr. William Short discuss special factors to consider when selecting HIV treatments during pregnancy, including:Key elements involved in evaluating ARV medications during pregnancy (eg, efficacy, pharmacokinetic, and safety data)Approach to optimizing ART regimens prior to and during pregnancyFaculty:Jean Rene Anderson, MDProfessorDepartment of Gynecology and ObstetricsJohns Hopkins UniversityDirector, Johns Hopkins HIV Women's Health ProgramJohns Hopkins Medical InstitutionsBaltimore, MarylandWilliam R. Short, MD, MPH, AAHIVSAssociate Professor of MedicineDivision of Infectious DiseasesDepartment of MedicinePerelman School of Medicine at the University of PennsylvaniaPhiladelphia, PennsylvaniaLink to full program:https://bit.ly/3PM3nYe Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

You can think of the “D” in HDV as standing for difficult, disadvantaged, and dangerous. Hepatitis delta virus (HDV) is difficult to diagnose, is often diagnosed in disadvantaged patient populations, and leads to dangerous sequelae.Listen as Dr. Kosh Agarwal and Dr. Graham R. Foster and discuss challenges and opportunities for linking patients to care after a positive test for HDV.Presenters:Kosh Agarwal, MDConsultant Hepatologist and Transplant PhysicianInstitute of Liver StudiesKing's College Hospital NHS Foundation TrustLondon, United KingdomGraham R. Foster, FRCP, PhDProfessor of HepatologyThe Liver UnitConsultant HepatologistQueen Mary University of LondonLondon, United KingdomLink to full program:https://bit.ly/3tlxa0H Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this episode, an international expert panel shares their thoughts on key considerations at the operational level for incorporating long-acting injectable antiretroviral therapy into the HIV treatment armamentarium. Topics include the duration of injection appointments in real-world settings, managing additional patient volume/workload (particularly the key role of nurses), and preventing and addressing planned and unplanned missed doses. Other episodes in this 4-part series cover additional aspects of long-acting antiretrovirals for HIV treatment and prevention, including:Key steps for switching patients to long-acting injectable cabotegravir plus rilpivirine for HIV treatment, such as selecting the most appropriate patients, introducing patients to the long-acting option, and preparing patients for what to expect from long-acting treatment in terms of efficacy, visit timing, and the injection experience Long-acting HIV pre-exposure prophylaxis What is still needed in long-acting HIV care to further address patient needs and inequities across subgroupsPresenters:Babafemi Taiwo, MBBSGene Stollerman Professor of MedicineChief, Division of Infectious DiseasesNorthwestern UniversityFeinberg School of MedicineChicago, IllinoisYvonne Gilleece, MB, BCh, BAOHonorary Clinical Professor in HIV Medicine and Sexual HealthDepartment of Global Health & HIVBrighton & Sussex Medical SchoolConsultant in HIV Medicine and Sexual HealthHIV DepartmentUniversity Hospitals Sussex NHS Foundation TrustBrighton, United Kingdom Cristina Mussini, MDHead of Department of Infectious Diseases and Tropical MedicineFull Professor of Infectious DiseasesInfectious Diseases Clinics, University HospitalUniversity of Modena and Reggio EmiliaModena, ItalyDarrell H. S. Tan, MD, FRCPC, PhDAssociate ProfessorDivision of Infectious DiseasesUniversity of TorontoClinician-ScientistDivision of Infectious DiseasesSt. Michael's HospitalToronto, CanadaContent based on an online CME/CE program supported by an independent educational grant from ViiV Healthcare. Link to full program:https://bit.ly/3P3uPBc Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this episode, an international expert panel shares their thoughts on key steps for switching patients to long-acting injectable cabotegravir plus rilpivirine for HIV treatment, including selecting the most appropriate patients, introducing patients to the long-acting option, and preparing patients for what to expect from long-acting treatment in terms of efficacy, visit timing, and the injection experience. Subsequent episodes in this 4-part series will cover additional aspects of long-acting antiretrovirals for HIV treatment and prevention, including operational planning, clinic impact, and handling missed doses with long-acting antiretroviral therapy for treatment; long-acting HIV pre-exposure prophylaxis; and what is still needed in long-acting HIV care to further address patient needs and inequities across subgroups.Presenters:Babafemi Taiwo, MBBSGene Stollerman Professor of MedicineChief, Division of Infectious DiseasesNorthwestern University Feinberg School of MedicineChicago, IllinoisYvonne Gilleece, MB, BCh, BAOHonorary Clinical Professor in HIV Medicine and Sexual HealthDepartment of Global Health & HIVBrighton & Sussex Medical SchoolConsultant in HIV Medicine and Sexual HealthHIV DepartmentUniversity Hospitals Sussex NHS Foundation TrustBrighton, United Kingdom Cristina Mussini, MDHead of Department of Infectious Diseases and Tropical MedicineFull Professor of Infectious DiseasesInfectious Diseases Clinics, University HospitalUniversity of Modena and Reggio EmiliaModena, ItalyDarrell H. S. Tan, MD, FRCPC, PhDAssociate ProfessorDivision of Infectious DiseasesUniversity of TorontoClinician-ScientistDivision of Infectious DiseasesSt. Michael's HospitalToronto, CanadaContent based on an online CME/CE program supported by an independent educational grant from ViiV Healthcare. Link to full program:https://bit.ly/3P3uPBc Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this episode, hear HIV activist Marc Thompson share his perspectives on aging with HIV including: His early experiences after receiving his diagnosisPersisting issues of the HIV epidemic including stigma and discriminationChanges in healthcare with the advent of HIV treatmentAdded issues of aging with HIV like polypharmacy, multimorbidity, and mental health concerns (eg, loneliness, social isolation)Actions needed to improve the path for the future: addressing opportunities to expand research, improve collaboration between HIV and other healthcare professionals and gain wisdom and knowledge from others aging with HIVPresenter:Marc ThompsonDirector, The Love TankLink to full program: https://bit.ly/3yIkntcYou can also join Marc Thompson and a panel of patient advocates and healthcare professionals in person or in a live simulcast as they discuss healthy aging with HIV at our live symposium at AIDS 2022 in Montreal, Quebec, Canada. They will discuss the challenges faced by older people with HIV, including medical and nonmedical issues, and specific challenges faced by subgroups of older patients such as women and patients in resource-limited settings. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this episode, Stefan Zeuzem, MD, discusses new viral hepatitis data from EASL 2022, including:Novel HBV therapeutics, including the REEF-2, B-Clear, and SAVE-1 studiesHBV cure from the Everest Project in ChinaHDV therapeutics from MYR301 and a study of bulevirtide in patients with cirrhosis and portal hypertensionHCV retreatment in patients with prior direct-acting antiviral therapy failurePresenter: Stefan Zeuzem, MDProfessor of MedicineChief, Department of Medicine I JW Goethe University Hospital Frankfurt, GermanyFollow along with the downloadable slideset at:https://bit.ly/3yJAruDLink to full program: https://bit.ly/3AjCNBC Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this episode, Nancy Reau, MD, discusses new viral hepatitis data from EASL 2022, including:Novel therapeutics for HBVTherapeutic vaccination for HBVEmerging treatment options for HDVHCV care cascadeHCC monitoring after HCV curePresenter: Nancy Reau, MDProfessor of MedicineChief, Section of HepatologyAssociate Director, Solid Organ TransplantationRichard B. Capps Chair of HepatologyRush University Medical CenterChicago, IllinoisFollow along with the downloadable slideset at: https://bit.ly/3yJAruDLink to full program:https://bit.ly/3IeUapm Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this episode, Carla S. Coffin, MD, MSc, shares her thoughts on the different investigational approaches under evaluation for their potential to achieve HBV cure, including entry inhibitors, capsid inhibitors, siRNAs, immune modulators, TLR agonists, therapeutic vaccines, and checkpoint inhibitors.Presenter:Carla S. Coffin, MD, MScProfessor of MedicineDivision of Gastroenterology and HepatologyDepartment of MedicineUniversity of CalgaryMedical Director of Calgary Liver UnitDivision of Gastroenterology and HepatologyDepartment of MedicineFoothills Medical CentreCalgary, Alberta, CanadaContent based on an online CME program supported by independent educational grants from AbbVie and Gilead Sciences, Inc. and developed in collaboration with the American Liver Foundation. Link to full program:https://bit.ly/3OGHvOv Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this episode, Yvette Raphael provides her perspectives and advice as an individual living with HIV in South Africa for more than 20 years. She shares her experiences and ideas for how to improve processes related to HIV diagnosis, care linkage, and treatment.Presenter:Yvette RaphaelContent based on an online CME program supported by an independent educational grant from Gilead Sciences, Inc.Link to full program: https://bit.ly/3tmgozy Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this episode, Pietro Lampertico, MD, PhD, discusses what to do when treatment for hepatitis B virus (HBV) infection is not indicated, covering topics such as:The different phases of chronic HBV infectionWhich patients in different phases require immediate HBV treatment and which can be monitored without therapyThe critical importance of ongoing monitoring for patients who do not meet indications for immediate therapyThe tests and frequency that should be used for monitoring patients not receiving HBV treatmentPresenter:Pietro Lampertico, MD, PhDProfessor of GastroenterologyDirector, Division of Gastroenterology and HepatologyIRCCS Ca Granda Policlinico HospitalUniversity of MilanMilan, ItalyContent based on an online CME program supported by independent educational grants from AbbVie and Gilead Sciences, Inc. and developed in collaboration with the American Liver Foundation. Link to full program: https://bit.ly/3OGHvOv Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this episode, Michelle D. Collins-Ogle, MD, FAAP, FPIDS, AAHIVS, explores the data and recommendations for HIV postexposure prophylaxis (PEP).Listen as she gives perspectives on:The CDC algorithm for evaluation and treatment of potential HIV exposuresThe CDC guideline preferred and alternative PEP antiretroviral therapy regimensData for the use of the single-tablet regimen bictegravir/emtricitabine/tenofovir alafenamide for PEPRecommended laboratory monitoring with PEPThe initiation of pre-exposure prophylaxis following a course of PEP, when appropriatePresenter:Michelle D. Collins-Ogle, MD, FAAP, FPIDS, AAHIVSAssistant Professor of PediatricsDivision of Pediatric Infectious DiseasesPediatric and Adolescent HIV Children’s Hospital at MontefiorePediatric Hospital of Albert Einstein College of MedicineBronx, New York Follow along with the slides at:https://bit.ly/3NBVXWNSee the entire program at:https://bit.ly/3fOl0XX Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this episode, Michelle D. Collins-Ogle, MD, FAAP, FPIDS, AAHIVS, explores key considerations for choosing antiretroviral therapy (ART) for pediatric patients.Listen as she gives perspectives on:Department of Health and Human Services (DHHS) guideline recommendations for infants at risk for perinatal HIV transmissionDHHS guideline–recommended ART regimens for childrenThe ODYSSEY A and B studies evaluating dolutegravir-based ART in children and adolescentsData for the use of the fixed-dose combination bictegravir/emtricitabine/tenofovir alafenamide in children and adolescentsKey ART and management considerations for adolescents and young adults with HIVPresenter:Michelle D. Collins-Ogle, MD, FAAP, FPIDS, AAHIVSAssistant Professor of PediatricsDivision of Pediatric Infectious DiseasesPediatric and Adolescent HIV Children’s Hospital at MontefiorePediatric Hospital of Albert Einstein College of MedicineBronx, New York Follow along with the slides at:https://bit.ly/3wMur29Link to full program:https://bit.ly/3fOl0XX Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this episode, Michelle D. Collins-Ogle, MD, FAAP, FPIDS, AAHIVS, explores key considerations for transgender people with HIV (PWH).Listen as she gives perspectives on:Department of Health and Human Services (DHHS) guideline recommendations for transgender PWHProviding HIV care within a gender-affirmative care model, including discussion of strategies, barriers, and facilitatorsGender-affirmative hormone therapy optionsDrug–drug interaction potential between gender-affirmative hormone therapy and antiretroviral therapyRecommended laboratory monitoring while receiving gender-affirming hormone therapyThe cascade of care for transgender PWH and barriers to engagement and retention in carePresenter:Michelle D. Collins-Ogle, MD, FAAP, FPIDS, AAHIVSAssistant Professor of PediatricsDivision of Pediatric Infectious DiseasesPediatric and Adolescent HIV Children’s Hospital at MontefiorePediatric Hospital of Albert Einstein College of MedicineBronx, New York Follow along with the slides at:https://bit.ly/3wOdKVoLink to full program:https://bit.ly/3fOl0XX Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this episode, Sharon R. Lewin, AO, FRACP, PhD, FAHMS, discusses: Principles for antiviral agent use in nonhospitalized patientsPreferred and alternative treatment optionsTreatment prioritization when there are logistical or supply constraintsOutpatient remdesivir usePINETREE data (adult patients)CARAVAN data (pediatric patients)FDA approval and treatment candidacyTherapeutic updatesIvermectin and the TOGETHER studyMonoclonal antibody use during current omicron eraPresenter: Sharon R. Lewin, AO, FRACP, PhD, FAHMSZDirector, The Peter Doherty Institute for Infection and ImmunityProfessor of Infectious DiseasesUniversity of MelbourneConsultant Infectious Diseases PhysicianAlfred Hospital and Royal Melbourne HospitalMelbourne, AustraliaReview the downloadable slideset at:https://bit.ly/3FXc90w Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this episode, Dexter James Wiseman, MD, discusses immunology and RSV vaccine development for older adults, including:Need for a vaccineEconomic burden of RSVReasons for poor outcomes in older adultsInvestigational vaccinesPresenter: Dexter James Wiseman, MDClinical Research FellowNHLIImperial CollegePhysicianRespiratory MedicineRoyal Brompton HospitalLondon, United KingdomReview the downloadable slideset and the full program at: https://bit.ly/3ydC8Ri Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this episode, Dexter James Wiseman, MD, discusses the epidemiology and risk factors for RSV in older adults, including:OverviewDisease burden based on ageSeasonalityImpact in care facilitiesEffects of the COVID-19 pandemicPresenter: Dexter James Wiseman, MDClinical Research FellowNHLIImperial CollegePhysicianRespiratory MedicineRoyal Brompton HospitalLondon, United KingdomReview the downloadable slideset and the full program at: https://bit.ly/3ydC8Ri Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this episode, Dexter James Wiseman, MD, discusses the impact and diagnosis of RSV in older adults, including:Risk factors for poor outcomesRSV vs influenza outcomesRSV symptomsRSV diagnosticsPresenter: Dexter James Wiseman, MDClinical Research FellowNHLIImperial CollegePhysicianRespiratory MedicineRoyal Brompton HospitalLondon, United KingdomReview the downloadable slideset and the full program at: https://bit.ly/3ydC8Ri Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this episode, listen as Robert G. Gish, MD, discusses key information on comparing current HBV vaccine formulations, and learn the best immunization practices for routine vaccination, including in special situations.Presenter:Robert G. Gish, MDProfessor of MedicineLoma Linda UniversityLoma Linda, CaliforniaAdjunct Professor of MedicineNevada School of MedicineLas Vega, NevadaClinical ProfessorUniversity of Nevada Reno School of MedicineReno, NevadaClinical ProfessorUniversity of California Skaggs School of Pharmacy and Pharmaceutical SciencesSan Diego, CaliforniaMedical DirectorHepatitis B FoundationWashington, DCReview the downloadable slidesets at:https://bit.ly/3LJPPLzLink to full program:https://bit.ly/3OZ50Ta Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this episode, learn about the importance of identifying adults at risk for reduced hepatitis B virus (HBV) seroprotection and applying current HBV vaccine recommendations in special populations. Listen as Robert G. Gish, MD, discusses key information on the identification and evaluation of patients who have chronic health conditions and therefore may be at risk for nonresponse to available vaccines.Presenter: Robert G. Gish, MDProfessor of MedicineLoma Linda UniversityLoma Linda, CaliforniaAdjunct Professor of MedicineNevada School of MedicineLas Vega, NevadaClinical ProfessorUniversity of Nevada Reno School of MedicineReno, NevadaClinical ProfessorUniversity of California Skaggs School of Pharmacy and Pharmaceutical SciencesSan Diego, CaliforniaMedical DirectorHepatitis B FoundationWashington, DCReview the downloadable slidesets at:https://bit.ly/3KPiJZzLink to full program:https://bit.ly/3OZ50Ta Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this episode, learn about the importance of hepatitis B virus (HBV) vaccination in adults. Listen as Robert G. Gish, MD, discusses key data on the burden and impact of HBV infection, and strategies to overcome barriers to HBV vaccination.Robert G. Gish, MDProfessor of MedicineLoma Linda UniversityLoma Linda, CaliforniaAdjunct Professor of MedicineNevada School of MedicineLas Vega, NevadaClinical ProfessorUniversity of Nevada Reno School of MedicineReno, NevadaClinical ProfessorUniversity of California Skaggs School of Pharmacy and Pharmaceutical SciencesSan Diego, CaliforniaMedical DirectorHepatitis B FoundationWashington, DCReview the downloadable slidesets at:https://bit.ly/3l1ZD8hLink to full program:https://bit.ly/3LMZn8E Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Hepatitis delta virus (HDV) is the most severe form of viral hepatitis, yet many patients go undiagnosed. Increasing HDV awareness is an important step to correct this and ensure that at-risk patients receive screening and then treatment and monitoring following a positive test. Hear Grace LH Wong, MD, and Ming-Lung Yu, MD, PhD, discuss a call to action to increase healthcare professional and patient awareness of HDV. Presenters: Grace LH Wong, MDProfessorDirector, Medical Data Analytics Centre (MDAC)Deputy Director, Center for Liver HealthAssistant Dean (Learning Experience), Faculty of MedicineThe Chinese University of Hong KongHonorary ConsultantDivision of Gastroenterology and HepatologyDepartment of Medicine and TherapeuticsPrince of Wales HospitalHong KongMing-Lung Yu, MD, PhDChair ProfessorHepatobiliary DivisionDepartment of Internal Medicine and Hepatitis CenterKaohsiung Medical UniversityVisiting StaffHepatobiliary DivisionDepartment of Internal MedicineKaohsiung Medical University HospitalKaohsiung City, TaiwanLink to full program: https://bit.ly/3tlxa0H Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this episode, Norah Terrault, MD, MPH, and a patient who has been cured of hepatitis C virus (HCV) infection discuss the importance of universal HCV testing for all adults, as well as the ease of curative therapies and the benefits of living with improved liver function post cure. This insightful discussion underscores how perceptions around HCV transmission risks and lack of symptoms serve as barriers to adequate screening and diagnosis, preventing curative treatment for many people with undiagnosed disease. The conversation also highlights the critical role of patient education and self-advocacy related to HCV infection, including what patients need to know and expect following cure.Presenters:Shelley RossellNorah Terrault, MD, MPHProfessor of MedicineChief of Gastrointestinal and Liver DiseasesUniversity of Southern CaliforniaLos Angeles, CaliforniaContent is based on an online CME program supported by independent educational grants from AbbVie and Gilead Sciences, Inc. and developed in collaboration with the American Liver Foundation. Link to full program:https://bit.ly/3OGHvOv Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this episode from the series “Key Decisions in HIV Care,” Cristina Mussini, MD, and William R. Short, MD, MPH, AAHIVS, discuss novel therapies for HIV prevention and treatment, including: PreventionCabotegravir for pre-exposure prophylaxis (PrEP) with the latest results from the HPTN 083 and HPTN 084 studiesNovel PrEP therapies in development, including islatravir and lenacapavirInitial therapyLenacapavir for initial therapy with results from the CALIBRATE studySwitch strategiesCabotegravir as a switch strategy with the latest results from the ATLAS-2M study, evaluating Q4W vs Q8W dosing, data on direct-to-inject without the oral lead-in, and data to date in pregnancyHeavily treatment–experienced patientsCurrently available novel therapies for heavily treatment–experienced patients, including fostemsavir and ibalizumabLenacapavir for heavily treatment–experienced patients with results from the CAPELLA studyPresenters:Cristina Mussini, MDHead of Department of Infectious Diseases and Tropical MedicineFull Professor of Infectious DiseasesInfectious Diseases Clinics, University HospitalUniversity of Modena and Reggio EmiliaReggio Emilia, Italy William R. Short, MD, MPH, AAHIVSAssociate Professor of MedicineDivision of Infectious DiseasesDepartment of MedicinePerelman School of Medicine at the University of PennsylvaniaPhiladelphia, Pennsylvania Content based on an online CME program supported by educational grants from Gilead Sciences, Inc.; Janssen Therapeutics, Division of Janssen Products, LP; and ViiV Healthcare.Follow along with the slides at:https://bit.ly/3vWhjHjLink to full program:https://bit.ly/3fOl0XX Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this podcast, Dr Dominique Laurent Braun discusses his micro-elimination program, the Swiss HCVree trial, designed to prevent hepatitis C virus (HCV) transmission among HIV-positive men who have sex with men. The study employed a test-and-treat approach to eliminate HCV infection in this key target population and could be a model for other countries to eliminate HCV infection in certain populations.Presenter:Dominique Laurent Braun, MDSenior Staff PhysicianDivision of Infectious Diseases and Hospital Epidemiology, University Hospital ZurichUniversity of ZurichZurich, SwitzerlandContent based on an online CME program supported by independent educational grants from AbbVie and Gilead Sciences.Link to full program: https://bit.ly/3OGHvOv Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Antiviral agents continue to be effective against different strains of SARS-CoV-2 when used early in the disease course. In this episode, learn about the role of antiviral agents in hospitalized and high-risk nonhospitalized patients with COVID-19 and in different age groups. Listen as David A. Wohl, MD, discusses when and how to use IV and oral antiviral agents including:Nirmatrelvir + ritonavirRemdesivirMolnupiravirPresenter:David A. Wohl, MDProfessor of MedicineSchool of MedicineSite Leader, Global Infectious Diseases Clinical Trials UnitUniversity of North Carolina at Chapel HillChapel Hill, North CarolinaReview the downloadable slidesets at:https://bit.ly/3Ou4tbELink to full program: https://bit.ly/3EBdf38 Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

The place of monoclonal antibodies in COVID-19 is changing. In this episode, learn about their role in prophylaxis of patients who are at high risk of complications from acquiring COVID-19 or treatment of high-risk patients who have a mild to moderate COVID-19 infection. Listen as Gregory Huhn, MD, MPHTM, discusses when and how to use monoclonal antibodies including:BebtelovimabCilgavimab/tixagevimabSotrovimabPresenter:Gregory Huhn, MD, MPHTMAssociate ProfessorDepartment of Infectious DiseasesRush University Medical CenterSenior Director of HIV ServicesDepartment of Infectious DiseasesCook County HealthChicago, IllinoisReview the downloadable slidesets at: https://bit.ly/3xOfu1ALink to full program: https://bit.ly/3EBdf38 Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this episode, Oluwaseun Falade-Nwulia, MBBS, MPH, and a patient with previous injection drug use who has been cured of HCV infection discuss critical barriers that are preventing more people with current or previous injection drug use from receiving appropriate HCV care.This insightful discussion underscores the negative effects of stigma toward people who inject drugs that exist in many clinical settings, the important role that socioeconomic factors such as transportation access and stable housing play in preventing access to HCV care, the effects of insufficient staffing at many addiction treatment centers, and the need for creative solutions to overcome these barriers.Presenter:Oluwaseun Falade-Nwulia, MBBS, MPH Associate ProfessorDivision of Infectious DiseasesJohns Hopkins University School of MedicineAttendingDivision of Infectious DiseasesJohns Hopkins HospitalBaltimore, MarylandContent based on an online CME program supported by independent educational grants from AbbVie and Gilead Sciences, Inc. and developed in collaboration with the American Liver Foundation.Link to full program:https://bit.ly/3KmJvZt Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this episode, Renslow Sherer, MD, discusses what is known to date regarding long COVID, also known as postacute sequelae of COVID-19 infection, including:Possible causes and risk factorsSigns and symptomsClinical managementTreatment options under considerationRole of vaccinationPresenter: Renslow Sherer, MDDirector, International HIV Training CenterProfessor of MedicineSection of Infectious Diseases and Global HealthDepartment of MedicineUniversity of ChicagoChicago, IllinoisReview the downloadable slideset and the full program at: https://bit.ly/3Ix8uZg Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In episode 7 of a series of sharing sessions between a physician and patient, Ming-Lung Yu, MD, PhD, and his patient, who is living with chronic hepatitis B, discuss:Role of family history in risk of hepatocellular carcinoma (HCC)Surveillance for HCCSteps to take when diagnosed with HCCHow to live a healthy life after HCC diagnosis and treatmentPresenter: Ming-Lung Yu, MD, PhDChair ProfessorHepatobiliary DivisionDepartment of Internal Medicine and Hepatitis CenterKaohsiung Medical UniversityVisiting StaffHepatobiliary DivisionDepartment of Internal MedicineKaohsiung Medical University HospitalKaohsiung City, TaiwanContent based on an online CME program supported by an independent educational grant from Gilead Sciences.Link to full program:https://bit.ly/37GY0cm Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Anti-inflammatory agents and immunomodulators are key components to treating patients who are severely or critically ill due to a COVID-19 infection.In this episode, Vikramjit Mukherjee, MD, discusses the role and timing of these treatment options, including:High-titer convalescent plasmaCorticosteroidsInterleukin-6 inhibitors (eg, tocilizumab)Janus kinase inhibitors (eg, baricitinib)Presenter:Vikramjit Mukherjee, MDAssistant Professor of MedicineDivision of Pulmonary, Critical Care, & Sleep MedicineNew York University School of MedicineDirector, Medical Intensive Care UnitBellevue HospitalNew York, New York Review the downloadable slidesets at: https://bit.ly/35NNb7QLink to full program: https://bit.ly/35SrxQ0 Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this episode from the series “Key Decisions in HIV Care,” Cristina Mussini, MD, and William R. Short, MD, MPH, AAHIVS, discuss important considerations for ART with opportunistic infections, including: When to start ART with pneumocystis pneumonia including discussion of the ACTG 5164 study of immediate vs delayed ART with opportunistic infectionsEACS, DHHS, and IAS-USA guideline recommendations for starting ART in the setting of most opportunistic infectionsConsiderations for the administration of ART to patients who are unable to swallow or critically ill and intubatedTreatment of Kaposi sarcoma and considerations for starting ART to avoid drug–drug interactions with Kaposi sarcoma treatmentConsiderations for starting ART with cytomegalovirus and the risk for IRIS from cytomegalovirusDiscussion of treatment of cytomegalovirus and overlapping toxicities between its treatment and ARTWhen to start ART with cryptococcal meningitis and the data to support delayed treatment initiation with this particular opportunistic infectionEACS, DHHS, and IAS-USA guideline recommendations for starting ART in the setting of cryptococcal meningitis specificallyTreatment of cryptococcal meningitis and managing drug–drug interactions between ART and antifungal therapyPresenters:Cristina Mussini, MDHead of Department of Infectious Diseases and Tropical MedicineFull Professor of Infectious DiseasesInfectious Diseases Clinics University HospitalUniversity of Modena and Reggio EmiliaReggio Emilia, Italy William R. Short, MD, MPH, AAHIVSAssociate Professor of MedicineDivision of Infectious DiseasesDepartment of MedicinePerelman School of Medicine at the University of PennsylvaniaPhiladelphia, Pennsylvania Content based on an online CME program supported by educational grants from Gilead Sciences, Inc.; Janssen Therapeutics, Division of Janssen Products, LP; and ViiV Healthcare.Follow along with the slides at:https://bit.ly/3uktrm1Link to full program:https://bit.ly/3q2DlGd Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this episode, Heiner Wedemeyer, MD, discusses HDV epidemiology beyond the United States, the features of HDV/HBV pathology, insights into screening and diagnostic approaches, key aspects of disease staging, new treatment options, and important remaining clinical questions regarding optimal management of HDV.Presenter:Heiner Wedemeyer, MDProfessor and ChairmanDepartment of Gastroenterology, Hepatology and EndocrinologyHannover Medical SchoolHannover, GermanyContent based on an online CME program supported by independent educational grants from AbbVie and Gilead Sciences, Inc. and developed in collaboration with the American Liver Foundation. Link to full program:https://bit.ly/3KmJvZt Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Episode 4 of this series features a conversation between a patient, Jason, and Paul Y. Kwo, MD, who discuss the particular challenges that can affect people with chronic hepatitis B seeking care in rural settings, including facing up to stigma, getting access to experienced medical practitioners, and searching for information and peer support.Presenter:Paul Y. Kwo, MDProfessor of MedicineDirector of HepatologyStanford University School of MedicinePalo Alto, CaliforniaContent based on an online CME program supported by independent educational grants from AbbVie and Gilead Sciences.Link to full program:https://bit.ly/3KmJvZt Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this episode from the series “Key Decisions in HIV Care,” Latesha Elopre, MD, MSPH, and Karine Lacombe, MD, PhD, discuss important considerations for PrEP in cisgender men and transgender women, including:Discussion of the PrEP gap and racial and gender disparities in PrEP access CDC, EACS, and WHO guidance on PrEP eligibility PrEP regimens currently recommended for adults and adolescents including FTC/TDF daily, FTC/TAF daily, and long-acting cabotegravir Data from clinical trials on the efficacy of FTC/TDF daily for men including Partners PrEP, TDF2, iPrEx, iPrEx OLE, and PROUD Data from the ANRS IPERGAY study on the use of FTC/TDF on demand Data from the DISCOVER trial on the use of FTC/TAF for PrEP Data from the HPTN 083 study on the use of long-acting cabotegravir as PrEP for cisgender men Clinical monitoring and considerations during PrEP usePresenters:Latesha Elopre, MDAssociate ProfessorDivision of Infectious DiseasesAssistant Dean of Diversity and InclusionGeneral Medical EducationUniversity of Alabama at BirminghamBirmingham, AlabamaKarine Lacombe, MD, PhDProfessorUMR-S1136Sorbonne UniversityHead, Infectious Diseases DepartmentSt Antoine Hospital, AP-HPParis, FranceContent based on an online CME program supported by educational grants from Gilead Sciences, Inc.; Janssen Therapeutics, Division of Janssen Products, LP; and ViiV Healthcare.Follow along with the slides at:https://bit.ly/3uqPje3Link to full program:https://bit.ly/3q2DlGd Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.